Keine Internetverbindung – die gespeicherte Version der Seite wird angezeigt.

TELIX Pharmaceuti…

AUAUD
← Zum Screener
AU:TLXUS:TLPPF

TELIX Pharmaceuticals Ltd (AU:TLX) — Biotechnology: Pharmaceutical Preparations. Anzahl der Börsen, an denen die Aktien des Unternehmens gehandelt werden: 2. Auf dieser Seite: Kurs und Chart, Dividenden, größte Aktionäre und Entwicklung der Aktienanzahl.

Über das Unternehmen

Website
telixpharma.com
Sektor
Health Care · Biotechnology: Pharmaceutical Preparations
Hauptsitz
NORTH MELBOURNE, Australia
CEO
Dr. Christian P. Behrenbruch BEng(Hons), DPhil(Oxon), GAICD, J.D., M.B.A., Ph.D
Mitarbeiter
1 120
Ausstehende Aktien
338.78 Mio.
Streubesitz
273.61 Mio.
Marktkapitalisierung
5.37 Mrd. AUD
Insider
15.81%
Institutionelle Anleger
34.17%
Branche (SIC)
Pharmaceutical Preparations
Beschreibung

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology; TLX252 for the treatment of patients with advanced metastatic kidney cancer; TLX400, a bladder fibroblast activation protein for treating various tumors; TLX102, a large amino acid transporter-targeting small molecule-based alpha therapy candidate for the treatment of glioblastoma and multiple myeloma; TLX300 for treating soft tissue sarcoma; and TLX090, a bone-seeking agent for bone metastases and pain palliation. In addition, it is developing BiPASS, which is in Phase 3 clinical trial for prostate cancer diagnosis; AlFluor, a novel PET radiochemistry solution; TLX250-Px, a PET diagnostic imaging agent; and TLX101-Px, a radiolabeled amino acid PET agent. It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally. The company has strategic collaboration with University Hospital Essen. The company was founded in 2015 and is headquartered in North Melbourne, Australia.

Börsen und Ticker

BörseTickerWährungPreisTyp
AU Australian Securities ExchangeTLX primärAUD—Stammaktie
US USA StocksTLPPF OTCUSD10.95 +1.39%Stammaktie

Kurs über 3 Monate

Tag mit Kursanstieg Tag mit Kursrückgang Ex-Dividenden-Tag ZahltagTag mit der Maus berühren / antippen — Eröffnungs-, Schluss-, Höchst- und Tiefstkurs

Dividenden

Keine Dividendenzahlungen gefunden (geprüft 08.10.2026). Das Unternehmen schüttet wahrscheinlich keine Dividenden aus.

Neuigkeiten diese Woche

Noch keine Nachrichten von der Website des Unternehmens.

Anzeige

Größte Anteilseigner

InhaberAnteilAktienBerichtsdatum
Behrenbruch (Christian P…≈6.31%21.4 Mio.2026-04-29
VANGUARD STAR FUNDS-Vang…1.21%4.1 Mio.2026-07-31
VANGUARD TAX-MANAGED FUN…0.81%2.74 Mio.2026-06-30
DFA INVESTMENT TRUST CO-…0.33%1.13 Mio.2026-07-31
VANGUARD Intl Eqy. INDEX…0.19%652 3312026-07-31
SCHWAB STRATEGIC TRUST-S…0.18%613 5272026-05-31
Fidelity Rutland Square…0.1%339 9652026-07-31
VANGUARD Intl Eqy. INDEX…0.09%298 3222026-07-31
VANGUARD Intl Eqy. INDEX…0.07%233 3212026-07-31
College Retirement Equit…0.06%202 5482026-06-30
Fidelity Salem Street Tr…0.05%156 8512026-07-31
Olson (Tiffany) (Indepen…≈0.03%106 5502025-03-05
McDonald (Marie Elizabet…≈0%3 7192025-03-05
Kluge (Andreas) (Former)—02024-10-17
McCann (Harry Kevin) (Fo…—02025-05-21